Chengdu Kanghong Biotech Co., Ltd.

21 clinical trials · Sponsor

Record	Firm	Date
First-In-Human Study of KHN922 for Injection (NCT07514975)	Chengdu Kanghong Biotech Co., Ltd.	2026-04-01
First-In-Human Study in Participants With Advanced Solid Tumors (NCT06885645)	Chengdu Kanghong Biotech Co., Ltd.	2025-04-30
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data (NCT04985448)	Chengdu Kanghong Biotech Co., Ltd.	2022-09-01
A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma (NCT04990271)	Chengdu Kanghong Biotech Co., Ltd.	2021-07-05
Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy (NCT04555304)	Chengdu Kanghong Biotech Co., Ltd.	2020-09-15
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization (NCT04215393)	Chengdu Kanghong Biotech Co., Ltd.	2019-07-18
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (NCT03630952)	Chengdu Kanghong Biotech Co., Ltd.	2018-12-21
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) (NCT03577899)	Chengdu Kanghong Biotech Co., Ltd.	2018-09-25

Every clearance here is in the API, with alerts when new ones post.